JP2016539134A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016539134A5 JP2016539134A5 JP2016535691A JP2016535691A JP2016539134A5 JP 2016539134 A5 JP2016539134 A5 JP 2016539134A5 JP 2016535691 A JP2016535691 A JP 2016535691A JP 2016535691 A JP2016535691 A JP 2016535691A JP 2016539134 A5 JP2016539134 A5 JP 2016539134A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- cancer
- inhibitor
- ezh2
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 25
- 239000003112 inhibitor Substances 0.000 claims 13
- 230000002401 inhibitory effect Effects 0.000 claims 13
- 102100016041 EZH2 Human genes 0.000 claims 10
- 101700041849 EZH2 Proteins 0.000 claims 10
- 201000011510 cancer Diseases 0.000 claims 9
- 239000003814 drug Substances 0.000 claims 6
- 206010025323 Lymphomas Diseases 0.000 claims 4
- 206010025310 Other lymphomas Diseases 0.000 claims 4
- 102100009749 BCR Human genes 0.000 claims 3
- 239000003862 glucocorticoid Substances 0.000 claims 3
- 206010012818 Diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 claims 2
- 238000002648 combination therapy Methods 0.000 claims 2
- 150000001875 compounds Chemical class 0.000 claims 2
- 239000000018 receptor agonist Substances 0.000 claims 2
- 230000001105 regulatory Effects 0.000 claims 2
- 230000003827 upregulation Effects 0.000 claims 2
- 102000010400 1-phosphatidylinositol-3-kinase activity proteins Human genes 0.000 claims 1
- 108040005185 1-phosphatidylinositol-3-kinase activity proteins Proteins 0.000 claims 1
- LQBVNQSMGBZMKD-UHFFFAOYSA-N 4-[4-[[2-(4-chlorophenyl)-4,4-dimethylcyclohexen-1-yl]methyl]piperazin-1-yl]-N-[3-nitro-4-(oxan-4-ylmethylamino)phenyl]sulfonyl-2-(1H-pyrrolo[2,3-b]pyridin-5-yloxy)benzamide Chemical compound C=1C=C(Cl)C=CC=1C=1CC(C)(C)CCC=1CN(CC1)CCN1C(C=C1OC=2C=C3C=CNC3=NC=2)=CC=C1C(=O)NS(=O)(=O)C(C=C1[N+]([O-])=O)=CC=C1NCC1CCOCC1 LQBVNQSMGBZMKD-UHFFFAOYSA-N 0.000 claims 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 1
- GXJABQQUPOEUTA-RDJZCZTQSA-N Bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims 1
- 229960003957 Dexamethasone Drugs 0.000 claims 1
- UREBDLICKHMUKA-CXSFZGCWSA-N Dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 1
- 229960004679 Doxorubicin Drugs 0.000 claims 1
- HKVAMNSJSFKALM-WDSGEKFTSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)\C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-WDSGEKFTSA-N 0.000 claims 1
- 210000001280 Germinal Center Anatomy 0.000 claims 1
- 239000002177 L01XE27 - Ibrutinib Substances 0.000 claims 1
- 102100013322 MTOR Human genes 0.000 claims 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N Prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 claims 1
- 206010070308 Refractory cancer Diseases 0.000 claims 1
- 108010001645 Rituximab Proteins 0.000 claims 1
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims 1
- 102100007756 TSC22D3 Human genes 0.000 claims 1
- 101710025489 TSC22D3 Proteins 0.000 claims 1
- LIRYPHYGHXZJBZ-UHFFFAOYSA-N Trametinib Chemical compound CC(=O)NC1=CC=CC(N2C(N(C3CC3)C(=O)C3=C(NC=4C(=CC(I)=CC=4)F)N(C)C(=O)C(C)=C32)=O)=C1 LIRYPHYGHXZJBZ-UHFFFAOYSA-N 0.000 claims 1
- 229940099039 Velcade Drugs 0.000 claims 1
- 229960001467 bortezomib Drugs 0.000 claims 1
- 229960005167 everolimus Drugs 0.000 claims 1
- XYFPWWZEPKGCCK-GOSISDBHSA-N ibrutinib Chemical compound C1=2C(N)=NC=NC=2N([C@H]2CN(CCC2)C(=O)C=C)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XYFPWWZEPKGCCK-GOSISDBHSA-N 0.000 claims 1
- 229960001507 ibrutinib Drugs 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000035772 mutation Effects 0.000 claims 1
- 229960005205 prednisolone Drugs 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- -1 tamatanib Chemical compound 0.000 claims 1
- 229960004066 trametinib Drugs 0.000 claims 1
- 229960001183 venetoclax Drugs 0.000 claims 1
Claims (24)
- 治療有効量のＥＺＨ２阻害剤を含む製剤を含有し、さらに治療有効量の標準癌治療剤を含む、癌治療の併用療法に使用される医薬組成物。
- ＥＺＨ２阻害剤および標準治療剤を含む混合物の治療有効量を含む癌治療用の医薬組成物。
- 前記癌が非ホジキンリンパ腫である請求項１又は２に記載の医薬組成物。
- 前記非ホジキンリンパ腫が、ＤＬＢＣＬ（びまん性大細胞型Ｂ細胞リンパ腫）またはＧＣＢ（胚中心Ｂ細胞様）リンパ腫である請求項３に記載の医薬組成物。
- 前記癌がＥＺＨ２野生型癌である請求項１又は２に記載の医薬組成物。
- 前記癌がＨ３Ｋ２７でのトリメチル化の増加を特徴とする請求項１又は２に記載の医薬組成物。
- 前記リンパ腫がＥＺＨ２突然変異型リンパ腫である請求項４に記載の医薬組成物。
- 前記ＥＺＨ２突然変異型リンパ腫が、Ｙ６４６、Ａ６８２またはＡ６９２の突然変異を有する請求項７に記載の医薬組成物。
- 前記癌がＥＺＨ２阻害剤抵抗性または難治性癌である請求項１又は２に記載の医薬組成物。
- 前記標準治療剤が、Ｒ−ＣＨＯＰ構成成分、ＢＣＬ阻害剤、またはＢＣＲ阻害剤からなる群から選択される１つまたは複数の化合物である請求項１〜９のいずれか一項に記載の医薬組成物。
- 前記Ｒ−ＣＨＯＰが、グルココルチコステロイド受容体アゴニストである請求項１０に記載の医薬組成物。
- 前記グルココルチコステロイド受容体アゴニストがプレドニゾロンまたはデキサメタゾンである請求項１１に記載の医薬組成物。
- ドキソルビシンがＲ−ＣＨＯＰから省略されている請求項１０に記載の医薬組成物。
- 前記ＢＣＬ阻害剤が、ナビトクラックス、オバトクラックスまたはＡＢＴ−１９９である請求項１０に記載の医薬組成物。
- 前記ＢＣＲ阻害剤が、ＰＩ３Ｋ／Ａｋｔ／ｍＴＯＲシグナル伝達カスケードの阻害剤である請求項１０に記載の医薬組成物。
- 前記ＢＣＲ阻害剤が、リツキシマブ、ＭＫ−２２０６、イデラリシブ、トラメチニブ、タマタニブ、エベロリムス、ベルケイド、またはイブルチニブである請求項１０に記載の医薬組成物。
- 前記ＥＺＨ２阻害剤が下記式を有する化合物またはその薬学的に許容される塩である請求項１〜１６のいずれか一項に記載の医薬組成物。
- 前記ＥＺＨ２阻害剤および標準治療剤は、同時にまたは逐次的投与用に適する請求項１〜１７のいずれか一項に記載の医薬組成物。
- 前記ＥＺＨ２阻害剤が、標準治療剤の投与前投与用に適する請求項１〜１７のいずれか一項に記載の医薬組成物。
- 混合が、少なくとも１つの遺伝子がアップレギュレートされた癌患者に投与するために用いられる請求項１〜１９のいずれか一項に記載の医薬組成物。
- 前記遺伝子が、セストリン、ＴＮＦおよびＧＩＬＺからなる群から選択される請求項２０に記載の医薬組成物。
- 前記遺伝子がグルココルチコイド標的遺伝子である請求項２０に記載の医薬組成物。
- 遺伝子のアップレギュレーションによって、請求項１に記載の医薬組成物におけるＥＺＨ２阻害剤の治療有効量が決定または調節されている請求項２０〜２２のいずれか一項に記載の医薬組成物。
- 遺伝子のアップレギュレーションによって、請求項１の併用療法における標準治療剤の治療有効量が決定または調節されている請求項２０〜２２のいずれか一項に記載の医薬組成物。
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361913063P | 2013-12-06 | 2013-12-06 | |
| US61/913,063 | 2013-12-06 | ||
| US201461934388P | 2014-01-31 | 2014-01-31 | |
| US61/934,388 | 2014-01-31 | ||
| US201461992881P | 2014-05-13 | 2014-05-13 | |
| US61/992,881 | 2014-05-13 | ||
| PCT/US2014/069167 WO2015085325A1 (en) | 2013-12-06 | 2014-12-08 | Combination therapy for treating cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019207594A Division JP2020045350A (ja) | 2013-12-06 | 2019-11-18 | 癌を治療するための併用療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016539134A JP2016539134A (ja) | 2016-12-15 |
| JP2016539134A5 true JP2016539134A5 (ja) | 2018-01-25 |
Family
ID=53274220
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016535691A Pending JP2016539134A (ja) | 2013-12-06 | 2014-12-08 | 癌を治療するための併用療法 |
| JP2019207594A Pending JP2020045350A (ja) | 2013-12-06 | 2019-11-18 | 癌を治療するための併用療法 |
| JP2021180722A Active JP7323592B2 (ja) | 2013-12-06 | 2021-11-05 | 癌を治療するための併用療法 |
| JP2023122130A Pending JP2023139230A (ja) | 2013-12-06 | 2023-07-27 | 癌を治療するための併用療法 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019207594A Pending JP2020045350A (ja) | 2013-12-06 | 2019-11-18 | 癌を治療するための併用療法 |
| JP2021180722A Active JP7323592B2 (ja) | 2013-12-06 | 2021-11-05 | 癌を治療するための併用療法 |
| JP2023122130A Pending JP2023139230A (ja) | 2013-12-06 | 2023-07-27 | 癌を治療するための併用療法 |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US20160303135A1 (ja) |
| EP (2) | EP3076977B1 (ja) |
| JP (4) | JP2016539134A (ja) |
| KR (3) | KR20220165809A (ja) |
| CN (2) | CN116019921A (ja) |
| AU (2) | AU2014360078A1 (ja) |
| BR (1) | BR112016012713A2 (ja) |
| CA (1) | CA2931263A1 (ja) |
| EA (1) | EA201691079A1 (ja) |
| ES (1) | ES2863996T3 (ja) |
| IL (3) | IL282741B2 (ja) |
| MX (1) | MX2016007351A (ja) |
| WO (1) | WO2015085325A1 (ja) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7125952B2 (ja) | 2017-05-18 | 2022-08-25 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 腫瘍を治療するための薬剤の製造におけるｂｔｋ阻害剤との組み合わせでのｅｚｈ２阻害剤の使用 |
Families Citing this family (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011160206A1 (en) | 2010-06-23 | 2011-12-29 | Morin Ryan D | Biomarkers for non-hodgkin lymphomas and uses thereof |
| US9175331B2 (en) * | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| SG11201406440TA (en) | 2012-04-13 | 2014-11-27 | Epizyme Inc | Combination therapy for treating cancer |
| US20150313906A1 (en) * | 2012-12-19 | 2015-11-05 | Glaxosmithkline Llc | Combination |
| PL3157527T3 (pl) | 2014-06-17 | 2023-08-07 | Epizyme, Inc. | Inhibitory ezh2 do leczenia chłoniaka |
| CN112168967A (zh) * | 2014-10-16 | 2021-01-05 | Epizyme股份有限公司 | 治疗癌症的方法 |
| EA201791095A1 (ru) | 2014-11-17 | 2017-10-31 | Эпизайм, Инк. | Способ лечения рака |
| SG10201902664RA (en) | 2015-04-20 | 2019-04-29 | Epizyme Inc | Combination therapy for treating cancer |
| JP6890097B2 (ja) | 2015-06-10 | 2021-06-18 | エピザイム，インコーポレイティド | リンパ腫を処置するためのｅｚｈ２阻害剤 |
| WO2017019721A2 (en) * | 2015-07-28 | 2017-02-02 | Constellation Pharmaceuticals, Inc. | Combination therapies for modulation of histone methyl modifying enzymes |
| AU2016312514A1 (en) | 2015-08-24 | 2018-03-15 | Epizyme, Inc. | Method for treating cancer |
| WO2017040190A1 (en) | 2015-08-28 | 2017-03-09 | Constellation Pharmaceuticals, Inc. | Crystalline forms of (r)-n-((4-methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1h-indole-3-carboxamide |
| AU2016333982A1 (en) * | 2015-10-06 | 2018-04-26 | Epizyme, Inc. | Method of treating medulloblastoma with an EZH2 inhibitor |
| WO2017100362A2 (en) * | 2015-12-07 | 2017-06-15 | Epizyme, Inc. | Inhibitors of ezh2 and methods of use thereof |
| US11951108B2 (en) | 2016-01-29 | 2024-04-09 | Epizyme, Inc. | Combination therapy for treating cancer |
| AU2017233898B2 (en) * | 2016-03-15 | 2022-12-15 | Oryzon Genomics, S.A. | Combinations of LSD1 inhibitors for use in the treatment of solid tumors |
| AU2017273726B2 (en) | 2016-06-01 | 2023-10-19 | Epizyme, Inc. | Use of EZH2 inhibitors for treating cancer |
| JP2019521988A (ja) * | 2016-06-17 | 2019-08-08 | エピザイム，インコーポレイティド | 癌を処置するためのｅｚｈ２阻害剤 |
| US11642346B2 (en) | 2017-03-31 | 2023-05-09 | Epizyme, Inc. | Combination therapy for treating cancer |
| US11602529B2 (en) | 2017-06-02 | 2023-03-14 | Epizyme, Inc. | Use of EZH2 inhibitors for treating cancer |
| US11452727B2 (en) | 2017-09-05 | 2022-09-27 | Epizyme, Inc. | Combination therapy for treating cancer |
| CN109718377B (zh) * | 2017-10-31 | 2021-03-26 | 中国科学院脑科学与智能技术卓越创新中心 | KPNB1抑制剂和Bcl-xL抑制剂在制备抗肿瘤药物中的应用 |
| WO2021026395A1 (en) * | 2019-08-06 | 2021-02-11 | The General Hospital Corporation | Compounds, pharmaceutical compositions, and methods of their use in reversing cancer chemoresistance |
| CN112870366B (zh) * | 2019-11-29 | 2023-01-24 | 江苏恒瑞医药股份有限公司 | Ezh2抑制剂在制备治疗肿瘤药物中的新用途 |
| US20210346525A1 (en) * | 2020-05-11 | 2021-11-11 | The University Of Chicago | Composition and methods for tumor imaging and treatment |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| US9175331B2 (en) | 2010-09-10 | 2015-11-03 | Epizyme, Inc. | Inhibitors of human EZH2, and methods of use thereof |
| PL2614369T3 (pl) | 2010-09-10 | 2016-08-31 | Epizyme Inc | Sposób określania przydatności inhibitorów ludzkiego ezh2 w leczeniu |
| AU2012223448B2 (en) | 2011-02-28 | 2017-03-16 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| JO3438B1 (ar) | 2011-04-13 | 2019-10-20 | Epizyme Inc | مركبات بنزين مستبدلة بأريل أو أريل غير متجانس |
| TW201733984A (zh) | 2011-04-13 | 2017-10-01 | 雅酶股份有限公司 | 經取代之苯化合物 |
| US9730925B2 (en) | 2011-09-30 | 2017-08-15 | Glaxomithkline Llc | Methods of treating cancer |
| KR102453519B1 (ko) | 2012-03-12 | 2022-10-11 | 에피자임, 인코포레이티드 | 인간 ｅｚｈ2의 억제제 및 이의 사용 방법 |
| SG11201406440TA (en) | 2012-04-13 | 2014-11-27 | Epizyme Inc | Combination therapy for treating cancer |
| EP4190777A1 (en) | 2012-04-13 | 2023-06-07 | Epizyme, Inc. | Hbr salt form for ezh2 inhibition |
| US9562041B2 (en) * | 2012-05-16 | 2017-02-07 | Glaxosmithkline Llc | Enhancer of zeste homolog 2 inhibitors |
| AU2013331380B2 (en) | 2012-10-15 | 2018-03-22 | Epizyme, Inc. | Substituted benzene compounds |
| MX2015004771A (es) | 2012-10-15 | 2016-01-08 | Epizyme Inc | Metodos para tratar cancer. |
| US20140120083A1 (en) * | 2012-11-01 | 2014-05-01 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
| CN105102000B (zh) | 2012-11-01 | 2021-10-22 | 无限药品公司 | 使用pi3激酶亚型调节剂的癌症疗法 |
| WO2014100646A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | 1,4-pyridone compounds |
| EP2935264B1 (en) | 2012-12-21 | 2017-10-18 | Epizyme, Inc. | 1,4-pyridone bicyclic heteroaryl compounds |
| EP2970306A4 (en) | 2013-03-15 | 2016-08-03 | Epizyme Inc | SUBSTITUTED BICYCLIC HETEROARYL COMPOUNDS CONDENSED IN 6.5 |
| WO2014172044A1 (en) | 2013-03-15 | 2014-10-23 | Epizyme, Inc. | Substituted benzene compounds |
| EP3811974A1 (en) | 2013-05-30 | 2021-04-28 | Infinity Pharmaceuticals, Inc. | Treatment of cancers using pi3 kinase isoform modulators |
| US10150764B2 (en) | 2013-07-19 | 2018-12-11 | Epizyme, Inc. | Substituted benzene compounds |
| EP3022195A2 (en) | 2013-07-19 | 2016-05-25 | Epizyme, Inc. | Substituted 6,5-fused bicyclic heteroaryl compounds |
| FI3057962T3 (fi) | 2013-10-16 | 2023-11-03 | Epizyme Inc | Hydrokloridisuolamuoto ezh2-estoon |
| EP3057594A4 (en) | 2013-10-18 | 2017-06-07 | Epizyme, Inc. | Method of treating cancer |
| PL3157527T3 (pl) | 2014-06-17 | 2023-08-07 | Epizyme, Inc. | Inhibitory ezh2 do leczenia chłoniaka |
| EA201791095A1 (ru) | 2014-11-17 | 2017-10-31 | Эпизайм, Инк. | Способ лечения рака |
| SG10201902664RA (en) | 2015-04-20 | 2019-04-29 | Epizyme Inc | Combination therapy for treating cancer |
| JP6890097B2 (ja) | 2015-06-10 | 2021-06-18 | エピザイム，インコーポレイティド | リンパ腫を処置するためのｅｚｈ２阻害剤 |
-
2014
- 2014-12-08 US US15/101,577 patent/US20160303135A1/en not_active Abandoned
- 2014-12-08 KR KR1020227041774A patent/KR20220165809A/ko not_active Application Discontinuation
- 2014-12-08 BR BR112016012713A patent/BR112016012713A2/pt not_active Application Discontinuation
- 2014-12-08 CN CN202310008463.1A patent/CN116019921A/zh active Pending
- 2014-12-08 WO PCT/US2014/069167 patent/WO2015085325A1/en active Application Filing
- 2014-12-08 IL IL282741A patent/IL282741B2/en unknown
- 2014-12-08 AU AU2014360078A patent/AU2014360078A1/en not_active Abandoned
- 2014-12-08 MX MX2016007351A patent/MX2016007351A/es active IP Right Grant
- 2014-12-08 CN CN201480071510.6A patent/CN105873592B/zh active Active
- 2014-12-08 EA EA201691079A patent/EA201691079A1/ru unknown
- 2014-12-08 ES ES14868382T patent/ES2863996T3/es active Active
- 2014-12-08 CA CA2931263A patent/CA2931263A1/en active Pending
- 2014-12-08 KR KR1020217029294A patent/KR20210117347A/ko not_active Application Discontinuation
- 2014-12-08 KR KR1020167017622A patent/KR102473113B1/ko active IP Right Grant
- 2014-12-08 JP JP2016535691A patent/JP2016539134A/ja active Pending
- 2014-12-08 EP EP14868382.4A patent/EP3076977B1/en active Active
- 2014-12-08 EP EP21159972.5A patent/EP3888659A1/en active Pending
-
2016
- 2016-05-19 IL IL245731A patent/IL245731B/en active IP Right Grant
-
2017
- 2017-11-10 US US15/809,445 patent/US10463671B2/en active Active
-
2019
- 2019-09-17 US US16/573,371 patent/US20200113911A1/en not_active Abandoned
- 2019-11-18 JP JP2019207594A patent/JP2020045350A/ja active Pending
-
2020
- 2020-03-24 AU AU2020202088A patent/AU2020202088B2/en active Active
-
2021
- 2021-11-05 JP JP2021180722A patent/JP7323592B2/ja active Active
- 2021-11-23 US US17/533,674 patent/US20220226336A1/en active Pending
-
2023
- 2023-07-27 JP JP2023122130A patent/JP2023139230A/ja active Pending
- 2023-07-30 IL IL304851A patent/IL304851A/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7125952B2 (ja) | 2017-05-18 | 2022-08-25 | 江蘇恒瑞医薬股▲ふん▼有限公司 | 腫瘍を治療するための薬剤の製造におけるｂｔｋ阻害剤との組み合わせでのｅｚｈ２阻害剤の使用 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016539134A5 (ja) | ||
| JP2017518334A5 (ja) | ||
| CY1125292T1 (el) | Παραγωγα 6,7,8,9-tetpaϋδpo-3h-πypazoλo[4,3-f iσοκινολινης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου | |
| MX2021000925A (es) | Inhibidores de inflamasoma nlrp3. | |
| JP2017518302A5 (ja) | ||
| BRPI0508461B8 (pt) | diaminopirimidinas, seus usos, e composição farmacêutica | |
| JP2016515561A5 (ja) | ||
| JP2020535173A (ja) | Ｈｓｐ９０阻害剤に関係する治療方法 | |
| JP2018522045A5 (ja) | ||
| JP2013542261A5 (ja) | ||
| JP2016534071A5 (ja) | ||
| EP2202222A3 (en) | Indene derivatives, their preparation and use as medicaments | |
| JP2016525097A5 (ja) | ||
| JP2016539156A5 (ja) | ||
| JP2012513416A5 (ja) | ||
| JP2017511377A5 (ja) | ||
| JP2015532296A5 (ja) | ||
| ECSP12011703A (es) | Composiciones farmacéuticas para el tratamiento del cáncer y otras enfermedades o trastornos | |
| BR112017017211A2 (pt) | composto, composição, sal farmaceuticamente aceitável de um composto, combinação, formulação farmacêutica, métodos para matar uma micobactéria e/ou inibir a replicação de micobactérias que causam doença em um animal, para tratamento de uma infecção micobacteriana em um animal e para tratamento de uma doença resultante de uma infecção por micobactéria de um mamífero, e, uso de um composto. | |
| RU2019141734A (ru) | Терапевтические соединения и композиции и способы их применения | |
| JP2022116304A (ja) | 血液がんの治療のためのＰＰＡＲγアゴニスト | |
| JP2017507151A5 (ja) | ||
| JP2016513124A5 (ja) | ||
| WO2018027084A3 (en) | Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer | |
| JP2018527360A5 (ja) |